Behandling med inhalationssteroid øger risiko for pneumoni ved kronisk obstruktiv lungesygdom

Mads Lumholdt, Janni Vagner Steenholt, Jørgen Vestbo

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

1 Citationer (Scopus)

Abstrakt

Inhaled corticosteroid treatment increases the risk of pneumonia in patients with COPD.
Clinical studies have suggested that inhaled corticosteroid (ICS) increases the frequency of pneumonia in patients with chronic obstructive pulmonary disease (COPD). This article summarizes the risk of pneumonia by reviewing the largest clinical studies addressing pneumonia as an adverse effect of ICS treatment. The collected data show that treatment of COPD patients with ICS increases the rate of pneumonia compared with β2-agonists or placebo. Physicians are recommended to follow guidelines and solely treat COPD patients with ICS if the patients are at high risk of exacerbations.
OriginalsprogDansk
ArtikelnummerV03140137
TidsskriftUgeskrift for Laeger
Vol/bind176
Sider (fra-til)1700-1703
StatusUdgivet - 1 sep. 2014
Udgivet eksterntJa

    Fingerprint

Bibliografisk note

Blad nummer: 18/2015

Citationsformater